{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T17:16:01Z","timestamp":1785086161702,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T00:00:00Z","timestamp":1651276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/M006174\/1"],"award-info":[{"award-number":["BB\/M006174\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015570","name":"Blood Cancer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015570","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mcponline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular &amp; Cellular Proteomics"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.mcpro.2022.100240","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T02:22:26Z","timestamp":1651458146000},"page":"100240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["eEF2K Activity Determines Synergy to Cotreatment of Cancer Cells With PI3K and MEK Inhibitors"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0861-7577","authenticated-orcid":false,"given":"Maruan","family":"Hijazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4207-9349","authenticated-orcid":false,"given":"Pedro","family":"Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3413-9150","authenticated-orcid":false,"given":"Nosheen","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6845-2789","authenticated-orcid":false,"given":"Saul","family":"Alvarez-Teijeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinothini","family":"Rajeeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3426-2274","authenticated-orcid":false,"given":"Pedro R.","family":"Cutillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcpro.2022.100240_bib1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","article-title":"The ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation","volume":"36","author":"Mendoza","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.mcpro.2022.100240_bib2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/msb.2011.27","article-title":"Strong negative feedback from Erk to Raf confers robustness to MAPK signalling","volume":"7","author":"Fritsche-Guenther","year":"2011","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.mcpro.2022.100240_bib3","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.cell.2016.07.007","article-title":"Phosphoproteome integration reveals patient-specific networks in prostate cancer","volume":"166","author":"Drake","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.mcpro.2022.100240_bib4","doi-asserted-by":"crossref","first-page":"rs6","DOI":"10.1126\/scisignal.2003573","article-title":"Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells","volume":"6","author":"Casado","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.mcpro.2022.100240_bib5","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41556-019-0328-z","article-title":"Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities","volume":"21","author":"Coppe","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.mcpro.2022.100240_bib6","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andre","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.mcpro.2022.100240_bib7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1074\/mcp.M112.017483","article-title":"Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance","volume":"11","author":"Alcolea","year":"2012","journal-title":"Mol. Cell Proteomics"},{"key":"10.1016\/j.mcpro.2022.100240_bib8","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1158\/2159-8290.CD-13-0063","article-title":"What a tangled web we weave: Emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway","volume":"3","author":"Klempner","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.mcpro.2022.100240_bib9","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1093\/neuonc\/nox044","article-title":"Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma","volume":"19","author":"McNeill","year":"2017","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.mcpro.2022.100240_bib10","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1158\/1535-7163.MCT-17-0207","article-title":"A\u00a0bifunctional MAPK\/PI3K antagonist for inhibition of tumor growth and metastasis","volume":"16","author":"Galban","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.mcpro.2022.100240_bib11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ygyno.2019.12.002","volume":"156","author":"Arend","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.mcpro.2022.100240_bib12","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11060-019-03227-7","article-title":"Phase I\/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed\/refractory glioblastoma (phase II)","volume":"144","author":"Hainsworth","year":"2019","journal-title":"J.\u00a0Neurooncol."},{"key":"10.1016\/j.mcpro.2022.100240_bib13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.clml.2019.03.015","article-title":"Oral MEK 1\/2 inhibitor trametinib in combination with AKT inhibitor GSK2141795 in patients with acute myeloid leukemia with RAS mutations: A phase II study","volume":"19","author":"Ragon","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.mcpro.2022.100240_bib14","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ymeth.2011.02.004","article-title":"Characterization of a TiO(2) enrichment method for label-free quantitative phosphoproteomics","volume":"54","author":"Montoya","year":"2011","journal-title":"Methods"},{"key":"10.1016\/j.mcpro.2022.100240_bib15","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1074\/mcp.M400219-MCP200","article-title":"Quantitative phosphoproteomics applied to the yeast pheromone signaling pathway","volume":"4","author":"Gruhler","year":"2005","journal-title":"Mol. Cell Proteomics"},{"key":"10.1016\/j.mcpro.2022.100240_bib16","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1074\/mcp.T500007-MCP200","article-title":"Highly selective enrichment of phosphorylated peptides from peptide mixtures using titanium dioxide microcolumns","volume":"4","author":"Larsen","year":"2005","journal-title":"Mol. Cell Proteomics"},{"key":"10.1016\/j.mcpro.2022.100240_bib17","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41375-018-0032-1","article-title":"Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells","volume":"32","author":"Casado","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.mcpro.2022.100240_bib18","doi-asserted-by":"crossref","first-page":"7719","DOI":"10.1073\/pnas.1423344112","article-title":"Empirical inference of circuitry and plasticity in a kinase signaling network","volume":"112","author":"Wilkes","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcpro.2022.100240_bib19","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1002\/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2","article-title":"Probability-based protein identification by searching sequence databases using mass spectrometry data","volume":"20","author":"Perkins","year":"1999","journal-title":"Electrophoresis"},{"key":"10.1016\/j.mcpro.2022.100240_bib20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/bs.mie.2016.09.021","article-title":"Targeted in-depth quantification of signaling using label-free mass spectrometry","volume":"585","author":"Cutillas","year":"2017","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.mcpro.2022.100240_bib21","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1074\/mcp.O116.064360","article-title":"Kinase activity ranking using phosphoproteomics data (KARP) quantifies the contribution of protein kinases to the regulation of cell viability","volume":"16","author":"Wilkes","year":"2017","journal-title":"Mol. Cell Proteomics"},{"key":"10.1016\/j.mcpro.2022.100240_bib22","article-title":"Autophagy inhibition contributes to the synergistic interaction between EGCG and doxorubicin to kill the hepatoma Hep3B cells","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.mcpro.2022.100240_bib23","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41587-019-0391-9","article-title":"Reconstructing kinase network topologies from phosphoproteomics data reveals cancer-associated rewiring","volume":"38","author":"Hijazi","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mcpro.2022.100240_bib24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-018-0008-7","article-title":"Targeting oncogenic Myc as a strategy for cancer treatment","volume":"3","author":"Chen","year":"2018","journal-title":"Signal. Transduct Target Ther."},{"key":"10.1016\/j.mcpro.2022.100240_bib25","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1093\/carcin\/bgs298","article-title":"53BP1 functions as a tumor suppressor in breast cancer via the inhibition of NF-kappaB through miR-146a","volume":"33","author":"Li","year":"2012","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.mcpro.2022.100240_bib26","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1128\/MCB.01035-14","article-title":"Eukaryotic elongation factor 2 kinase activity is controlled by multiple inputs from oncogenic signaling","volume":"34","author":"Wang","year":"2014","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.mcpro.2022.100240_bib27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/aps.2015.123","article-title":"Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases","volume":"37","author":"Liu","year":"2016","journal-title":"Acta Pharmacol. Sin"},{"key":"10.1016\/j.mcpro.2022.100240_bib28","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1093\/emboj\/20.16.4370","article-title":"Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase","volume":"20","author":"Wang","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.mcpro.2022.100240_bib29","doi-asserted-by":"crossref","first-page":"43951","DOI":"10.1074\/jbc.M111.301291","article-title":"1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) induces phosphorylation of eukaryotic elongation factor-2 (eEF2): A cautionary note on the anticancer mechanism of an eEF2 kinase inhibitor","volume":"286","author":"Chen","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.mcpro.2022.100240_bib30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jbior.2014.04.003","article-title":"Eukaryotic elongation factor 2 kinase, an unusual enzyme with multiple roles","volume":"55","author":"Kenney","year":"2014","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.mcpro.2022.100240_bib31","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/s41467-021-22170-8","article-title":"Drug ranking using machine learning systematically predicts the efficacy of anti-cancer drugs","volume":"12","author":"Gerdes","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcpro.2022.100240_bib32","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1042\/BJ20111530","article-title":"Identification of autophosphorylation sites in eukaryotic elongation factor-2 kinase","volume":"442","author":"Pyr Dit Ruys","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.mcpro.2022.100240_bib33","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1128\/MCB.01665-08","article-title":"Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth","volume":"29","author":"Acosta-Jaquez","year":"2009","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.mcpro.2022.100240_bib34","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1128\/MCB.24.7.2986-2997.2004","article-title":"A\u00a0novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin","volume":"24","author":"Browne","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.mcpro.2022.100240_bib35","doi-asserted-by":"crossref","first-page":"26089","DOI":"10.1074\/jbc.M504045200","article-title":"Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase","volume":"280","author":"Holz","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.mcpro.2022.100240_bib36","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.4475","article-title":"Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor-positive advanced breast cancer: A phase 1b clinical trial","volume":"5","author":"Juric","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.mcpro.2022.100240_bib37","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s40265-017-0838-6","article-title":"Copanlisib: First global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.mcpro.2022.100240_bib38","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s40265-018-1013-4","article-title":"Duvelisib: First global approval","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.mcpro.2022.100240_bib39","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s40265-014-0285-6","article-title":"Idelalisib: First global approval","volume":"74","author":"Markham","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.mcpro.2022.100240_bib40","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10637-019-00776-6","article-title":"Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors","volume":"38","author":"Shapiro","year":"2020","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.mcpro.2022.100240_bib41","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1093\/emboj\/20.16.4360","article-title":"A\u00a0novel method to identify protein kinase substrates: eEF2 kinase is phosphorylated and inhibited by SAPK4\/p38delta","volume":"20","author":"Knebel","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.mcpro.2022.100240_bib42","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/emboj.2008.39","article-title":"cdc2-cyclin B regulates eEF2 kinase activity in a cell cycle- and amino acid-dependent manner","volume":"27","author":"Smith","year":"2008","journal-title":"EMBO J."},{"key":"10.1016\/j.mcpro.2022.100240_bib43","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1186\/s12885-016-2853-5","article-title":"Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways","volume":"16","author":"Liu","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.mcpro.2022.100240_bib44","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1158\/0008-5472.CAN-10-2889","article-title":"eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206","volume":"71","author":"Cheng","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.mcpro.2022.100240_bib45","doi-asserted-by":"crossref","first-page":"D442","DOI":"10.1093\/nar\/gky1106","article-title":"The PRIDE database and related tools and resources in 2019: Improving support for quantification data","volume":"47","author":"Perez-Riverol","year":"2019","journal-title":"Nucl. Acids Res."}],"container-title":["Molecular &amp; Cellular Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535947622000482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535947622000482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:09:20Z","timestamp":1761527360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535947622000482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1535947622000482"],"URL":"https:\/\/doi.org\/10.1016\/j.mcpro.2022.100240","relation":{},"ISSN":["1535-9476"],"issn-type":[{"value":"1535-9476","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"eEF2K Activity Determines Synergy to Cotreatment of Cancer Cells With PI3K and MEK Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Molecular & Cellular Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcpro.2022.100240","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"100240"}}